CDT CONDUIT PHARMACEUTICALS INC

Conduit to Change Name to CDT Equity Inc.

Conduit to Change Name to CDT Equity Inc.

  • Name change to CDT Equity Inc. reflects evolution of strategy and focus on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation, strategic partnerships and out-licensing

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit" or the “Company”) today announce that it intends to change its name to CDT Equity Inc. (“CDT”) reflecting the evolution of its strategy as a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel therapeutic treatments.

CDT’s strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies despite strong Phase I safety data. Through advanced co-crystallization and solid-form technologies developed at our Cambridge facility, we aim to improve drug properties and have successfully extended patent life of certain drugs by up to 20 years. Our current pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health.

Our collaboration with Sarborg enables CDT to apply proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. Sarborg’s insights have directly informed two new combination patent filings, strengthening our intellectual property portfolio. In addition, CDT has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention. CDT look to progress out-licensing opportunities based on this data, if these trials are successful.

A further partnership with Manoira enables CDT to expand the scope of its drug portfolio into the animal health market in a cost-efficient manner. This collaboration allows CDT to accelerate the understanding of the mechanism of action, safety, and potential efficacy of its portfolio across multiple species, while retaining 100% ownership of all data and intellectual property generated relating for human applications. This is expected to enhance the core human therapeutic pipeline but also opens potential new revenue streams in the high-growth veterinary market.

Repositioning CDT enables the company to explore multiple opportunities in the healthcare, biotech and broader technology innovation. The Board of CDT continue to evaluate a cryptocurrency treasury reserve strategy, working with consultants to best advise a novel market which has seen significant recent activity and success for respective stakeholders. Long-term exposure to digital assets can present both strategic and financial benefits as part of a diversified capital management approach.

“Operating with a lean, disease-agnostic model, CDT Equity Inc. prioritizes speed, adaptability, and capital efficiency. We avoid the cost burden of late-stage clinical trials, focusing instead on high-leverage development strategies,” said Dr. Andrew Regan, Chief Executive. “Looking ahead, we are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.”

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit's future results of operations and financial position, Conduit's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavours with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under "Risk Factors" therein, and in other filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.

Investors & Media:



EN
05/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONDUIT PHARMACEUTICALS INC

 PRESS RELEASE

Conduit to Change Name to CDT Equity Inc.

Conduit to Change Name to CDT Equity Inc. Name change to CDT Equity Inc. reflects evolution of strategy and focus on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation, strategic partnerships and out-licensing NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit" or the “Company”) today announce that it intends to change its name to CDT Equity Inc. (“CDT”) reflecting the evolution of its strategy as a data-driven biotech development company focused on identifying,...

 PRESS RELEASE

Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy

Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy Independent advisor appointed to assess feasibility and strategic benefit of a partial cryptocurrency-based treasury reserveInitiative aims to diversify capital positioning while retaining focus on IP-driven pharmaceutical development NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 08, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) (“Conduit” or the “Company”) today announced that it has engaged a third-party consultant to evaluate and advise on the potential adoption of a part cryptocurrency tre...

 PRESS RELEASE

Conduit Pharmaceuticals Files New Patents Following AI-Driven Combinat...

Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit" or the “Company”) today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company’s first patent f...

 PRESS RELEASE

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoir...

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health marketEvaluation of AZD5658 expands Conduit’s glucokinase activator platform into novel veterinary applications, complementing AZD1656 developmentCost-efficient approach enhances Conduit’s pipeline while preserving full ownership of intellectual property and data, maxi...

 PRESS RELEASE

Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market

Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s application to transf...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch